7th Annual MIBio Conference
MIBio 2017: Stability of Biopharmaceuticals – From Molecular Interactions to Successful Products
Wednesday 4th October Downing College, Cambridge
The MIBio conference series engages world leading experts from industry and academia in a discussion on how the latest molecular interaction based discoveries can be exploited in biopharmaceutical formulation to produce more effective, patient-friendly and safer therapeutic products.
Whilst monoclonal antibodies still dominate the product pipelines, there is an increasing number of different product types in development including antibody fragments, protein conjugates, bispecific /tri-specific antibodies, cell and gene therapy products and more complex formats, as well as a large variety of peptides or nucleotides, each with specific stability and drug delivery challenges. MIBio 2017 will focus on discussing these challenges as well as the latest advances in understanding molecular interactions, formulation strategies and device options to overcome them.
MIBio 2017 expects more than 100 industrial and academic research attendees to create an interesting and stimulating event fostering new collaborations and discoveries that will help steer the development of the next generation of formulation technologies. We will be inviting abstracts for poster submissions and welcome applications for sponsor and exhibitor slots on the day. We look forward to seeing you at MIBio 2017!
MIBio 2017 is organised by the Formulation Science and Technology Group (FSTG) and the Joint Colloids Group (SCI) of the Royal Society of Chemistry (RSC) together with the Academy of Pharmaceutical Sciences (APS). The event will be held on 4th October 2017 at the Howard Theatre, Downing College, Cambridge, Cambridge, UK.
The MIBio 2017 organising committee is:
- Jan Jezek (Arecor)
- Nicholas J. Darton (Arecor)
- Tejash Shah (GSK)
- Stephen Harding (University of Nottingham)
- Bernardo Perez-Ramirez (Sanofi)